AuthorisedTherapeutic use (Phase IV)Interventional

Sample Collection Study to Monitor the Risk of Malignancy Due to Insertional Oncogenesis in Early Onset Patients with Metachromatic Leukodystrophy Treated with OTL-200 in the Clinical Development Program

Metachromatic leukodystrophy (MLD) is a rare, inherited condition that damages the nervous system. Libmeldy is an approved gene therapy that works by replacing a faulty gene inside a patient's own blood-forming stem cells. Because gene therapies insert new genetic material, doctors keep a close eye on patients for many years after treatment. This Phase 4 safety study collects samples from adults who received Libmeldy in earlier clinical trials when they were younger. Researchers want to monitor for rare long-term risks, such as the new gene accidentally triggering uncontrolled cell growth or blood cancers. Participants do not receive any new medicines; instead, they provide blood or other samples during routine health checks. This ongoing monitoring gives patients reassurance and helps medical teams protect their long-term health.

At a glance

Status

Authorised

Phase

Therapeutic use (Phase IV)

Sponsor

Orchard Therapeutics (Europe) Limited

Enrolment target

Start

22 Jun 2026

Metachromatic leukodystrophy

What is this study about?

Metachromatic leukodystrophy (MLD) is a rare, life-limiting genetic condition. In people with MLD, a missing enzyme leads to a harmful build-up of fatty substances that damages the protective coating around nerves. Libmeldy is a pioneering gene therapy designed to treat early-onset MLD. It works by taking a patient's own stem cells, adding a working copy of the missing gene in a laboratory, and returning the cells to the body.

While gene therapies can be life-changing, scientists must monitor their long-term safety very carefully. When new genetic instructions are placed inside a cell, there is a small theoretical risk that they might land near other sensitive genes. If this happens, it could disrupt how cells divide and grow, potentially leading to abnormal cell growth or blood cancers. Doctors call this process insertional oncogenesis.

This study is designed to track this specific risk over time. Researchers will test regular blood and tissue samples from people who received Libmeldy in earlier trials. They look for early warning signs, such as whether a single group of modified cells is starting to multiply much faster than the others. Catching these changes early means doctors can step in quickly if any health issues arise.

Long-term follow-up studies like this are standard practice for modern gene therapies. They give individuals and their families peace of mind that their health is being closely watched, while also gathering vital scientific knowledge that will make future genetic treatments even safer.

Key takeaways

This study tracks the long-term safety of the gene therapy Libmeldy in adults treated for MLD.
It checks for rare risks such as abnormal cell growth or blood cancers.
Participation involves routine sample collections, such as blood tests, rather than new medicines.
Tests are often combined with your regular hospital visits to keep things simple.
Taking part helps protect your health through close monitoring and supports future gene therapy safety.

Who may be eligible?

This study is designed specifically for adults aged 18 and over who have already received Libmeldy (also known as OTL-200) as part of an earlier clinical trial for early-onset metachromatic leukodystrophy. Both men and women are eligible to take part.

You cannot join this study if you have not previously been treated with Libmeldy in an earlier clinical research trial. This study is only for long-term health monitoring and does not provide gene therapy to people who are looking for new treatment for MLD.

If you or a family member received this gene therapy in the past and have now reached adulthood, your specialist hospital doctor can confirm whether your previous trial participation makes you eligible for this follow-up study.

Could this study suit you?

Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.

Are you aged 18 or older?
Were you diagnosed with early-onset metachromatic leukodystrophy (MLD)?
Did you receive Libmeldy (OTL-200) gene therapy as part of an earlier clinical trial?
Are you willing to provide blood or tissue samples during scheduled hospital visits?

Answer every question to see your result.

What does participation involve?

Taking part in this study is straightforward and does not involve taking any new medications. Instead, it involves attending planned hospital visits where the research team will collect samples, such as routine blood tests. In most cases, these sample collections will be scheduled alongside your regular clinic appointments to keep travel to a minimum. The medical team will check your overall health, review your medical history, and send your samples to specialist laboratories for detailed genetic analysis. Because this is a long-term safety monitoring study, participation may continue over several years so doctors can build a complete picture of your health as you get older.

Potential risks and benefits

The main benefit of taking part is that your health and blood cells will be closely watched by leading gene therapy specialists, meaning any unexpected changes can be detected and managed as early as possible. You will also help improve the safety of gene therapy for future patients. The physical risks are very low and mainly relate to routine blood draws, which can cause brief discomfort, slight bruising, or light-headedness. Being monitored for rare health risks can sometimes cause worry, but your care team is there to support you. You are always free to withdraw from the study at any point, and doing so will never affect your standard medical care.

Locations (5)

Some site locations are approximate. We're improving this — please verify with the trial team before travelling.

—
Unverified
Netherlands
—
Unverified
Germany
—
Unverified
Italy
—
Unverified
Sweden
—
Unverified
France

Common questions

Will I receive a new treatment in this study?

No. This study does not test any new drugs. It is a monitoring study that collects blood and tissue samples from people who already received Libmeldy in the past.

What does insertional oncogenesis mean?

It is a rare potential side effect of gene therapy where the newly inserted gene lands in a place that accidentally triggers cells to grow out of control, which could lead to cancer.

How often will I need to give samples?

Sample collection is usually scheduled alongside your regular specialist hospital check-ups, so you should not need many extra appointments.

What happens if the researchers find something unusual in my blood?

If tests show signs of abnormal cell growth, your study doctor will discuss the findings with you straight away and arrange further checks or care as needed.

Do I have to pay to take part?

No. Clinical trial assessments and tests are free, and many studies offer help with travel costs to and from hospital visits.